Main results of the Ouabain and Adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin

Jan A. Staessen,Lutgarde Thijs,Katarzyna Stolarz-Skrzypek,Antonella Bacchieri,John Barton,Ezio degli Espositi,Peter W. de Leeuw,Mirosław Dłużniewski,Nicola Glorioso,Andrzej Januszewicz,Paolo Manunta,Viktor Milyagin,Yuri Nikitin,Miroslav Souček,Chiara Lanzani,Lorena Citterio,Mario Timio,Andrzej Tykarski,Patrizia Ferrari,Giovanni Valentini,Kalina Kawecka-Jaszcz,Giuseppe Bianchi

Main results of the Ouabain and Adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin

2011

The Ouabain and Adducin for Specific Intervention on Sodium in Hypertension (OASIS-HT) Trial was a phase-2 dose-finding study of rostafuroxin, a digitoxygenin derivative, which selectively antagonizes the effects of endogenous ouabain (EO) on Na+,K+-ATPase and mutated adducin. Rostafuroxin lowered blood pressure (BP) in some animal models and in humans.

Keywords:

Sodium
Aldosterone
Losartan
Medicine
Ouabain
Blood pressure
Plasma renin activity
Renin–angiotensin system
Crossover study
Endocrinology
Internal medicine
Diabetes mellitus
Placebo

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations